Go to navigation Go to content Ray Hodge & Associates, LLC
Comments Off on Onglyza


Onglyza (saxagliptin) is an oral medication used to help control blood sugar in people with type 2 diabetes. It is in a class of drugs commonly referred to as gliptins, and is not used to treat type 1 diabetes. Onglyza can have serious side effects, including pancreatitis, and has been shown to increase your risk of heart failure by 27%. Onglyza use has been linked to an increased risk of pancreatic cancer and thyroid cancer. If you believe that your injuries or the death of a loved one were caused by Onglyza, the Kansas defective drug attorneys of Ray Hodge & Associates, LLC, are here to help.

What is Onglyza?

Onglyza is used, along with diet and exercise, to lower blood sugar in people with type 2 diabetes. It may be used alone or in combination with other drugs. Onglyza is in a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, more commonly known as gliptins.

Gliptins work by blocking an enzyme called DPP-4. DPP-4 removes a hormone called incretin from your body. Incretin stimulates insulin production and decreases the amount of glucose released from the liver as needed. In people without diabetes, incretin is released throughout the day and levels increase at meal times. Then it needs to be removed. Some people with type 2 diabetes do not produce enough incretin, so blocking DPP-4 can help them keep the incretin they do produce in their bodies, improving blood sugar control.

Onglyza Dangers

Onglyza can have serious side effects including:

• Heart failure
• Pancreatitis
• Skin reactions
• Joint pain
• Fluid retention
• Allergic reaction

Some studies have shown and increased risk of pancreatic cancer and thyroid cancer with Onglyza use.

Onglyza Heart Failure Risk

Studies have found an increased risk of heart failure in people taking Onglyza. A study published in the New England Journal of Medicine, in October 2013, found an increased risk of heart failure with Onglyza use. A U.S. Food and Drug Administration (FDA) advisory committee reviewed the results of a study called Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) and found that there was a 27% increase in first time hospitalizations for heart failure in Onglyza users.

If you have developed heart failure, pancreatitis, or other serious injuries after taking Onglyza, you may be able to recover compensation for your losses in a lawsuit. You have a limited amount of time to take legal action. Please call Ray Hodge & Associates, LLC, at (316)269-1414 or contact us online today to schedule your free initial consultation.

Back to Top

Ray Hodge & Associates proudly represents victims and their families across the state of Kansas, including Wichita, Andover, Derby, Goddard, Haysville, Mulvane, Rose Hill, Newton, El Dorado and Hutchinson. Call today for a free consultation all over the state of Kansas. We have proudly served clients in Sedgwick, Butler, Sumner, Harvey, Kingman and Reno Counties.